Head-To-Head Review: Mateon Therapeutics (MATN) and SIGA Technologies (SIGA)
Mateon Therapeutics (OTCMKTS: MATN) and SIGA Technologies (OTCMKTS:SIGA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Insider and Institutional Ownership
6.7% of SIGA Technologies shares are owned by institutional investors. 4.5% of Mateon Therapeutics shares are owned by company insiders. Comparatively, 4.7% of SIGA Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of recent ratings and target prices for Mateon Therapeutics and SIGA Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mateon Therapeutics presently has a consensus target price of $1.75, suggesting a potential upside of 686.52%. Given Mateon Therapeutics’ higher possible upside, research analysts plainly believe Mateon Therapeutics is more favorable than SIGA Technologies.
Earnings and Valuation
This table compares Mateon Therapeutics and SIGA Technologies’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mateon Therapeutics||N/A||N/A||-$13.65 million||($0.56)||-0.40|
|SIGA Technologies||$14.99 million||25.27||-$39.69 million||($0.49)||-9.80|
Mateon Therapeutics has higher earnings, but lower revenue than SIGA Technologies. SIGA Technologies is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Mateon Therapeutics and SIGA Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Mateon Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
SIGA Technologies beats Mateon Therapeutics on 6 of the 11 factors compared between the two stocks.
About Mateon Therapeutics
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
About SIGA Technologies
SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.
Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.